Nurix Therapeutics, Inc. (NRIX) fundamentals score
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 9.0 out of 10, Mixed fundamentals
- Growth: 9.2/10
- Profitability: 10.0/10
- Financial health: 9.8/10
- Earnings quality: 5.5/10
- Valuation: 9.3/10
Scores are calculated from Nurix Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-08. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10
- Globus Medical, Inc. (GMED): 8.4/10